NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.

@article{Wang2008NKcellAA,
  title={NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.},
  author={S Wang and Emilian Racila and Ronald P Taylor and George J Weiner},
  journal={Blood},
  year={2008},
  volume={111 3},
  pages={
          1456-63
        }
}
Antibody-dependent cellular cytotoxicity (ADCC) and complement fixation both appear to play a role in mediating antitumor effects of monoclonal antibodies (mAbs), including rituximab. We evaluated the relationship between rituximab-induced complement fixation, natural killer (NK)-cell activation, and NK cell-mediated ADCC. Down-modulation of NK- cell CD16 and NK-cell activation induced by rituximab-coated target cells was blocked by human serum but not heat-inactivated serum. This inhibition… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 79 extracted citations

Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.

Expert opinion on biological therapy • 2013
View 6 Excerpts
Highly Influenced

Resistance to Immunotherapeutic Antibodies in Cancer

Resistance to Targeted Anti-Cancer Therapeutics • 2013
View 20 Excerpts
Highly Influenced

Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2017

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Similar Papers

Loading similar papers…